DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) – NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer, as it advances multiple...
Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection...
New Funding Structure Includes Redemption Rights, Ownership Limitations, and Conversion Floor as Investors Monitor Upcoming Clinical UpdatesHouston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies...
NeOnc Technologies Advances Novel Neuro-Oncology Therapies Targeting Glioblastoma and Other Hard-to-Treat Brain CancersHouston, Texas--(Newsfile Corp. - June 9, 2026) - For years, artificial intelligence...
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud...
DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – NeOnc Technologies (NASDAQ: NTHI ), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS)...
CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company advancing two Phase...
DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction,...
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money...
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing...